We are pleased to announce that Dr. Zanos was recently invited to appear on the Cyprus Broadcasting Corporation (RIK) to discuss our laboratory’s groundbreaking clinical trial investigating ketamine as a treatment for opioid use disorder (OUD).

This pioneering study—the first of its kind in Cyprus—is being conducted at the “GEFYRA” (BRIDGE) Substitute Substance Unit in collaboration with the State Health Services Organisation in Cyprus (OKYPY). Designed as a double-blind, placebo-controlled trial, it aims to evaluate ketamine’s potential in preventing relapse and prolonging abstinence in OUD patients, particularly those with co-occurring depression.

This research marks a significant milestone for clinical studies in Cyprus, paving the way for future innovative trials in the country. By addressing the complex challenges faced by individuals with OUD and comorbid depression—an often underdiagnosed and undertreated condition that can severely impact recovery—our trial seeks to fill a crucial gap in treatment strategies.

Through this rigorous investigation, funded by the Research and Innovation Foundation, our laboratory is advancing evidence-based treatments for substance use disorders while establishing a foundation for future clinical research initiatives in Cyprus.

We look forward to sharing updates as this important study progresses. This research exemplifies our commitment to developing novel therapeutic approaches for complex psychiatric conditions and expanding the frontiers of clinical research in Cyprus.

For more details, visit the official clinical trial registry: EU Clinical Trials Register – Ketamine for OUD Study.